Fly News Breaks for March 12, 2015
KYTH
Mar 12, 2015 | 07:12 EDT
Leerink raised its price target for KYTHERA to $61 saying the unanimous FDA panel confirms the "highly favorable" benefit/risk profile of ATX-101. The firm estimates the company's takeout value at $85 per share and keeps an Outperform rating on the name.
News For KYTH From the Last 2 Days
There are no results for your query KYTH